Neo7logix is a real time surveillance in real time technology producing a design within 24-48 hours as a multi- mechanism design, which included replication proteins, molecular transcription signals and receptors and both humoral and cellular adaptive immune responses that included the loss of T Cell responses that are neutralized by the virus as observed by the COVID-19 research community.
Our precision bioscience cloud-based unification maps, ranks and types to the world population HLA allele expression integrating molecular changes and receptor expressions that need to be targeted in the total design at any stage of viral evolution and production of mutant variants.
Our platform engineering allows us to quickly design for any mutational shift in the advancing viral ecology. Our design is in the preclinical process and not currently approved by the FDA. However, Neo7logix is advancing interest and action for FDA compliance. Our SOLVx was evaluated by CEPI during a Techtalk and our Neo7logix SOLVx-COVID-19 is considered by the panel as a very favorable design and we were advised to advance further with our preclinical process.
SOLVx-Disease-X
Neo7logix SOLVx-Disease-X is based upon the similar platform design as SOLVx-COVID-19. The difference is we focus upon other threatening fast replicating novel viruses that could fast become a pandemic threat to the world population. We have focused on the top viral list produced by WHO, CDC and authoritative agencies.
Similarly, we utilize real time surveillance and real time technology as outlined in our SOLVx-COVID-19, as well as, all of the Neo7logix bioscience cloud-based unification precision, mapping, ranking, HLA typing and molecular protein / receptor pathways involved in immune editing design selections.
These designs are also in preclinical process and not approved by the FDA currently. However, we are moving along to meet regulatory compliance.
Please contact if interested in discussing further: office@neo7logix.com